Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor, AML, and Cancer Stem Cell Targeting.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD44 and CD44v6 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Standard CD44s) | CD44s ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/μg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View CD44 Products |
| Antigen (CD44v6) | CD44v6 ECD-Fc Fusion Protein Cancer Stem Cell isoform target. High purity (>95%), Endotoxin <1EU/μg. Sequence Verified. HEK293 Expressed. |
View CD44v6 Products |
| Gene Delivery | CD44 Lentivirus Premade Particles Full-length ORF for stable cell lines. Supports internalization and cell-based assays. |
View CD44 Products |
| Benchmark Ab | Anti-CD44v6 (Biosimilar Sequence) or Anti-CD44 (Research Grade) Recombinant positive controls for assay validation. |
View CD44 Products |
| Validator | CD44 siRNA Set For knockdown verification and specificity checks. |
View CD44 Products |
| Ligand | SPP1 (Osteopontin) ECD-Fc Primary CD44 ligand for competitive binding and HA disruption assays. |
View SPP1 Products |
| Related Target A | EGFR Co-receptor signaling network in epithelial cancers; synergy with CD44v6. |
View EGFR Products |
| Related Target B | MET Synergistic pathway driver in metastasis and resistance; CD44v6 is co-receptor. |
View MET Products |
| Related Target C | CD33 Synergistic AML target for combination therapy. |
View CD33 Products |
| Related Target D | ALDH1A1 Intracellular cancer stem cell marker for combination studies. |
View ALDH1A1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Cross-Reactivity (v6 vs Standard) | Separate bioengineered ECD-Fc constructs for CD44s and CD44v6; sequence verified by Mass Spec. Ensures absolute epitope specificity. |
| Cross-Species Evaluation (Human/Mouse/Cyno) | Orthologous proteins available with >95% purity and matched glycosylation profiles for cynomolgus monkey and mouse. |
| Glycosylation-Dependent Binding | HEK293 expressed (native glycosylation) preserves critical structural conformation; essential for HA binding assays. |
| Hyaluronic Acid Competition & Internalization | High-purity antigens retain native conformation for HA-binding disruption; lentivirus stable lines enable pH-sensitive dye internalization kinetics. |
| Lack of Reliable Controls / False Positives | Clinical benchmark antibodies (biosimilar) and validated siRNA sets included for assay standardization and definitive specificity checks. |
Live CD44 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD44-targeted therapeutics is intensifying. Early clinical candidates (e.g., RG7356) targeting pan-CD44 faced significant skin toxicity and target-mediated drug disposition (sink effect) due to ubiquitous CD44 expression on normal tissues. The field has pivoted decisively toward CD44 splicing variants, particularly CD44v6, which is preferentially expressed on cancer stem cells and AML blasts. The next wave of R&D includes isoform-selective Antibody-Drug Conjugates (ADCs), CAR-T therapies, and bispecific antibodies. Emerging strategies also involve HA-disruption inhibitors to block metastasis. The critical success factors now are exquisite specificity for variant exons, robust internalization for ADC payload delivery, and careful cross-species evaluation for preclinical safety.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Isoform-Selective) | Various Biotechs & Academic Institutions | Head & Neck, Breast Cancer, AML, Solid Tumors | Internalization assay & CD44v6 vs CD44s selectivity: need high-purity CD44v6 ECD-Fc and lentiviral stable lines. |
| CAR-T Cell Therapy | Multiple Research Hospitals & Cell Therapy Innovators | AML, ALL, Solid Tumors | Binding specificities against variants vs WT: need distinct variant proteins and lentivirus for cell-based killing assay. |
| Bispecific Antibodies | Emerging Startups & Preclinical Biotechs | Metastatic Carcinomas, CSC Eradication | Avidity measurement & heterodimer validation: need cross-reactive Abs and target panels. |
| HA-Disruption Inhibitor | Research Groups | Metastasis Prevention | Competitive binding assay: need SPP1 and CD44 ECD pairs for HA-binding disruption. |